- Home
- IMTX vs PHVS Comparison
IMTX vs PHVS Comparison
Compare IMTX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- PHVS
- Stock Information
- Founded
- IMTX N/A
- PHVS 2015
- Country
- IMTX Germany
- PHVS Netherlands
- Employees
- IMTX N/A
- PHVS N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- PHVS Health Care
- Exchange
- IMTX Nasdaq
- PHVS Nasdaq
- Market Cap
- IMTX 954.2M
- PHVS 1.0B
- IPO Year
- IMTX N/A
- PHVS 2021
- Fundamental
- Price
- IMTX $5.35
- PHVS $18.36
- Analyst Decision
- IMTX Strong Buy
- PHVS Strong Buy
- Analyst Count
- IMTX 4
- PHVS 5
- Target Price
- IMTX $16.67
- PHVS $40.60
- AVG Volume (30 Days)
- IMTX 988.8K
- PHVS 47.5K
- Earning Date
- IMTX 11-18-2024
- PHVS 11-13-2024
- Dividend Yield
- IMTX N/A
- PHVS N/A
- EPS Growth
- IMTX N/A
- PHVS N/A
- EPS
- IMTX N/A
- PHVS N/A
- Revenue
- IMTX $128,824,447.00
- PHVS N/A
- Revenue This Year
- IMTX $116.22
- PHVS N/A
- Revenue Next Year
- IMTX N/A
- PHVS N/A
- P/E Ratio
- IMTX N/A
- PHVS N/A
- Revenue Growth
- IMTX 52.53
- PHVS N/A
- 52 Week Low
- IMTX $5.28
- PHVS $15.21
- 52 Week High
- IMTX $13.77
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- IMTX 21.22
- PHVS 48.93
- Support Level
- IMTX $7.00
- PHVS $15.21
- Resistance Level
- IMTX $7.42
- PHVS $19.59
- Average True Range (ATR)
- IMTX 0.41
- PHVS 1.39
- MACD
- IMTX -0.14
- PHVS -0.02
- Stochastic Oscillator
- IMTX 2.90
- PHVS 67.31
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.